RxCelerate Launch Galaxy™: A Next-Generation Antibody Discovery Platform

RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Galaxy™, that offers significant advantages over the current generation of tools for delivery of new therapeutic monoclonal antibodies. “Monoclonal antibodies make up almost a third of new drug approvals in the last three years and represent … Read more

Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

Avexegen Therapeutics Inc. today announced that it has received a Phase 2 award of $2.94 million under the National Institutes of Health’s Small Business Innovation Research Program (SBIR) for the development of an oral Neuregulin-4-based therapy for inflammatory bowel disease (IBD). IBD affects over 3 million patients in the US and is almost equally manifested … Read more

The Innovative Prosthetic Urology Portfolio From Rigicon Receives Marketing Approval in Australia

Rigicon Inc., with its global headquarters in NY, USA, announces that their innovative prosthetic urology portfolio received marketing approval from Australia (Australian Government Department of Health Therapeutic Goods Administration). The following implant options from Rigicon are now available for specialized surgeons and patients in Australia: With this approval, Rigicon becomes the first medical device solutions … Read more

Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300

Polaryx Therapeutics, Inc., a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that it has received both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Krabbe Disease (a.k.a. Globoid Cell Leukodystrophy) with PLX-300 from the U.S. Food and Drug Administration (FDA). Krabbe disease (KD) is a rare, heritable metabolic genetic disorder that affects … Read more

Native Cardio to Present at the Georgetown and Maryland PNP University Pitch Session

Native Cardio, Inc., a cardiac medical device manufacturer located in Naples, Florida, dedicated to developing medical devices to improve the outcomes of patients suffering from acute and chronic atrial fibrillation, announced today that Joe Pergolizzi, M.D., President and Chief Executive Officer, will be presenting at the Georgetown and Maryland PNP University Pitch Session scheduled for … Read more

TriRadial Solutions Recognized for Contributions to BioNTech COVID-19 Vaccine

BioNTech (www.biontech.de) has recognized global biopharma consulting firm TriRadial Solutions for its work in helping to accelerate the company’s record-breaking achievement of bringing a COVID-19 vaccine to market. https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-recognizes-employees-and-partners-their-support “It has been a privilege and an honor to work with Ugur Sahin, Özlem Türeci and the entire BioNTech team over the past two years,” said Geoff Garabedian, … Read more

Nemysis Granted Patent on Its Nano-Particulate Oral Iron Product (IHAT) in South Africa

Nemysis Limited, the Dublin based pharmaceutical and healthcare company, focused on Iron Deficiency/Anemia and Gluten Sensitivity, today announced that the South Africa Patent and Trademark Office has issued S.A. Patent No.ZA201802192, with claims of Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses, directed to the use of oral iron supplementation. … Read more

Inova Appoints Claude Basset as Chief Product Officer

Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer.   Inova is a French Tech success story that, now in its 10th year, has captured more than half of the partnering platform market amongst the world’s largest pharmaceutical companies. Inova’s technology helps more than 150 biopharma … Read more

Akelos Inc.’s SAB Member Co-Authors Paper Validating HCN1 as a Therapeutic Target for the Treatment of Peripheral Neuropathic Pain

Dr. Peter Goldstein, scientific co-founder of Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, has just co-authored a review article in the peer-reviewed journal Current Neuropharmacology (doi: 10.2174/1570159X19666210119153047. Online ahead of print) that highlights the rationale for targeting HCN1 in sensory neurons for … Read more